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A B S T R A C T
Amyloid β 1–42 peptide (Aβ1–42) accumulates in Alzheimer's disease (AD) that is toxic to the basal forebrain
cholinergic (BFC) neurons in substantia innominata-nucleus basalis magnocellularis complex (SI-NBM).
Transient Receptor Potential Ankyrin1 (TRPA1) receptor is present in murine brain, however its role in neu-
rotoxic processes is unclear. We investigated the Aβ1–42-induced neurotoxicity in TRPA1 wild-type (TRPA1+/+)
and knockout (TRPA1−/−) mice.
Expression and neuroanatomical localization of TRPA1 receptor were examined using RT qPCR. Cholinergic
fibre loss was determined on acetylcholinesterase (AChE) stained brain slices, and choline acetyltransferase
(ChAT) immunohistochemistry was used to assess the cholinergic cell loss. Novel object recognition (NOR),
radial arm maze (RAM) and Y-maze tests were used to investigate memory loss.
Aβ1–42-injected WT mice showed marked loss of cholinergic fibres and cell bodies, which was significantly
attenuated in TRPA1−/− animals. According to the NOR and RAM tests, pronounced memory loss was detected
in Aβ1–42-injected TRPA1+/+ mice, but not in TRPA1−/− group.
Our findings demonstrate that TRPA1 KO animals show substantially reduced morphological damage and
memory loss after Aβ1–42 injection in the SI-NBM. We conclude that TRPA1 receptors may play an important
deteriorating role in the Aβ1–42-induced cholinergic neurotoxicity and the consequent memory loss in the murine
brain.
1. Introduction
One of the major pathomorphological hallmarks of Alzheimer’s
disease (AD) is the significant neuronal death in the cortex, hippo-
campus and basal forebrain. The cholinergic system of the basal fore-
brain (BFC) is the pivotal source of cholinergic connections to the
cortex and hippocampus, which plays a major role in attention and
memory (Zaborszky et al., 1999; Beninger et al., 2001). Accumulation
of neurotoxic β-amyloid peptides, such as Aβ1–42 contributes to neu-
ronal loss in BFC in AD (Maccioni et al., 2001). The Aβ activates as-
trocytes and microglial cells, also it has direct neurotoxic effect by li-
gand-like interaction with the N-methyl-D-aspartate (NMDA) glutamate
receptors (Harkany et al., 2000). Aβ1–42 microinjection into the nucleus
basalis magnocellularis (NBM) results in severe damage of neurons in
BFC and memory deficits in rodents (Harkany et al., 2000, 1998;
Giovannelli et al., 1995; Kwakowsky et al., 2016).
There is an increasing evidence that neuro-immune interactions
may play a critical role in the pathomechanism of several neurode-
generative diseases (Candore et al., 2007; Masters et al., 2015, Sághy
et al., 2016) and regulatory role of the transient receptor potential
(TRP) ion channels is strongly suggested in these processes. TRP re-
ceptors form non-selective cation channels, with preferentially high
calcium ion permeability. Calcium influx triggers several intracellular
pathways. TRP channels are sensitive for various stimuli including
mechanical, thermal triggers or chemical ligands. Considering these
interactions, they are likely to be sensors for several physiological or
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pathophysiological stimuli (Khalil et al., 2018). One of the TRP re-
ceptors, the transient receptor potential ankyrin 1 (TRPA1) is best
known as a sensor for environmental irritants participating in pain, cold
and itch sensation. TRPA1 has a wide range of ligands; specifically it is
sensitive to low and high temperature, osmotic changes, natural and
synthetic irritants. Several TRPA1 agonists are reactive electrophilic
ligands (Zimova et al., 2018). Channel gating effect of these compounds
is based on covalent modification of cysteine and lysine residues within
the N-terminus and transmembrane domains of the receptor (Zygmunt
and Högesättt, 2014). Since TRPA1 can be triggered by endogenous
compounds generated by tissue injury and inflammation, it can be a
potential target for anti-nociceptive and anti-inflammatory drug can-
didates (Nishida et al., 2015; Horváth et al., 2016). Recent data showed
that TRPA1 receptors are also expressed in the brain and play mod-
ulatory role in neurodegenerative disorders and neuroinflammation,
such as multiple sclerosis and AD (Sághy et al., 2016, Lee et al., 2016;
Bölcskei et al., 2018; Dalenogare et al., 2020; Ritter et al., 2020).
TRPA1 channels have also been found on astrocytes of corpus callosum
(Sághy et al., 2016), also in oligodendrocytes of the cerebellum
(Hamilton et al., 2016) and in the endothelium of cerebral arteries
(Sullivan et al., 2015; Pires and Earley, 2018). Nowadays, Lee and
colleagues have provided immunohistochemical evidence that hippo-
campal astrocytes express TRPA1 in wild-type mice; and im-
munoreactivity of the receptor protein also occurs in the cortical neu-
rons of amyloid precursor protein/presenilin1 (APP/PS1) transgenic
mice (Lee et al., 2016). However, only few in vivo data are available to
corroborate the function of TRPA1 in the brain. The principal aims of
the present study were to investigate the morphological and the func-
tional aspects of TRPA1-mediated events in BFC using Aβ1–42-induced
neurotoxicity model in TRPA1 knockout mice.
2. Materials and methods
2.1. Animals
Experiments were carried out on 3–4 month-old male C57BL/6,
TRPA1 knockout mice (TRPA1−/−) and their wild-type siblings
(TRPA1+/+) (obtained from Prof. P. Geppetti, University of Florence,
Italy). The animals were bred and kept in the Animal House of the
Department of Pharmacology and Pharmacotherapy of the University of
Pécs at 24 °C and provided with standard rodent food and water ad
libitum. Mice were housed under conditions of 12-h light/dark cycle in
groups of 3–5 in polycarbonate cages (530 cm2 floor space, 14 cm
height) on wood shavings bedding. The animals had a 60-min accli-
matization period prior to each behavioural experiment. Six animal
groups were created, stated as untreated wild-type (TRPA1+/+ naïve)
and TRPA1 receptor gene-deficient mice (TRPA1−/− naïve), vehicle-
injected wild-type (TRPA1+/+ Veh) and TRPA1 knockout (TRPA1−/−
Veh), β-amyloid-treated wild-type (TRPA1+/+ Aβ1–42), and TRPA1
knockout (TRPA1−/− Aβ1–42). Eight TRPA1+/+ and seven TRPA1-/-
animals were used for AChE histochemistry. Eight TRPA1+/+ and six
TRPA1-/- mice prepared for ChAT immunohistochemistry. In beha-
vioural measurements the number of animals was 12−12 in TRPA1+/+
naïve and TRPA1-/- naïve groups, 8−8 in TRPA1+/+ Veh and TRPA1-/-
Veh groups, 10 in TRPA1+/+ Aβ1–42 group and 12 in TRPA1-/- Aβ1–42
group. All experimental procedures were approved by the Animal
Welfare Committee of University of Pécs, licence no.: BA 02/2000−24/
2016, BA 02/2000−38/2016.
2.2. Preparation of Aβ1–42 peptide samples
Aβ1–42 was expressed recombinantly in E. coli and purified ac-
cording to Ikenoue and colleagues (Ikenoue et al., 2014). Briefly, the
DNA sequence coding the human Aβ1–42 peptide was artificially con-
structed using codons preferred by E. coli with an extra Met residue at
the N-terminal of the peptide. The DNA construct was inserted into
pAED4 vector (Doering and Matsudaira, 1996) and the protein ex-
pression was carried out in E. coli BL21 (DE3) pLysS strain (Novagen,
Inc., Madison, WI), using 1 mM IPTG for induction. The peptide accu-
mulated in the inclusion bodies of the bacterial cells. The purified in-
clusion bodies were solubilized in 20 mM NaOH and the peptide was
further purified by repeated cycles of amyloid growth at low pH and
monomerization in hexafluoroisopropanol combined with centrifuga-
tion steps. The monomeric lyophilized peptide was first dissolved in 10
mM NaOH on ice, then it was diluted into appropriate amount of TBS
buffer resulting in a final concentration of 300 μM peptide and a pH of
7.4. The solution was aged for 5 days at room temperature. Before
administration, the solution was spun down in a tabletop centrifuge at
15,000 g for 2 min to remove larger aggregates.
2.3. Aβ1–42 injection
Mice were anesthetized with isoflurane, mounted in a stereotaxic
apparatus, and slowly injected (0.1 μl/min) with 1 μl of aged Aβ1–42
diluted in Tris-buffered saline (TBS) into the SI-NBM of the right
hemisphere for the morphological studies or bilaterally for the beha-
vioural studies. Aβ1–42 was injected at the stereotaxic coordinates re-
lative to Bregma at anteroposterior (−0.7 mm) and mediolateral (−2
mm), and dorsoventral from dura mater (−3.75 and−4.75 mm, 0.5 μl
at both coordinates). Based on previously published results the 300 μM
Aβ1–42 dose and the 12-day survival time were chosen (Kwakowsky
et al., 2016) for morphological and behavioural experiments (Fig. 1).
2.4. Measurement of Trpa1 expression
Brains and trigeminal ganglia of TRPA1+/+ (n = 6) and TRPA1−/−
mice (n = 6) were quickly dissected after decapitation. The samples
were immediately frozen in liquid nitrogen and stored at−80 °C. Then,
brains were sliced by razor blades using a coronal brain matrix (cat.nr.
15050, Ted Pella, Redding, CA) to obtain 1 mm coronal sections
(Palkovits et al., 1978). A microdissection needle (cat.nr. 15091, Ted
Pella) of 1 mm diameter was used to collect micropunches containing
the following brain areas in the marked coronal planes (the distances of
coronal sections from the Bregma were indicated in brackets: SI-NBM
(0-(−1 mm)), hippocampus and somatosensory cortex (−1 mm-(−2
mm)) (Paxinos and Franklin, 2001). Total RNA content was isolated
using Direct-zol RNA MiniPrep kit (Zymo Research, cat.nr: R2060),
according to the manufacturer’s instruction. Samples were diluted to
equal amount of total RNA and cDNA pools were generated by reverse
transcription using Maxima First Strand cDNA Synthesis kit (Thermo
Fisher Scientific, cat.nr: K1971). The expression level of Trpa1 mRNA
was determined with Stratagene Mx3000 qPCR instrument using
custom-designed Trpa1 TaqMan assay (forward primer: atgccttcag-
caccccattg, reverse primer: gacctcagcaatgtccccaa, probe: 56FAMtggg-
cagctZENtattgccttcacaat3IABkFQ) and normalised with the predesigned
hypoxanthine phosphoribosyltransferase (Hprt) TaqMan assay
(Mm.PT.39a.22214828). The thermal cycling was initiated at 95 °C for
5 min followed by 45 cycles of 35 s at 95 °C and 30 s at 62 °C and 1 min
synthesis at 72 °C. Primers and probes were obtained from IDT, Leuven,
Belgium.
2.5. Immunohistochemistry
To examine the cholinergic cell loss in the SI-NBM, ChAT im-
munohistochemistry was accomplished with free-floating technique
(Kwakowsky et al., 2016). To determine the rate of cholinergic fibre
loss in the somatosensory cortex, AChE histochemistry with silver ni-
trate intensification was performed (Koszegi et al., 2011). On day 13,
Aβ1–42-injected and non-injected control animals were deeply an-
esthetized and perfused as described above. Dissected brains were
postfixed for 4 h at room temperature, then incubated overnight in 30
% sucrose diluted in phosphate buffer. Four sets of 30 um thick coronal
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sections were cut on a freezing microtome (Leica, Germany).
2.6. Behavioural experiments and analysis
2.6.1. Novel object recognition test (NOR)
NOR tests the recognition memory (Li et al., 2011; Bevins and
Besheer, 2006; D’Souza et al., 2015). We applied a 3-day-long protocol.
On day 1, mice were allowed to move around in the 45 × 45 × 30 cm
wooden box for 5 min. On day 2, animals were let freely explore two
identical objects for 5 min. On day 3 (24 h later), the animals were
presented to one familiar and one novel object, which was similar in
size but different in color and shape compared to the familiar one
(Fig. 4A). Mice could explore the objects freely for 5 min. Behaviour of
animals was video-recorded and analysed with Ethovision XT 11 soft-
ware (Noldus Information Technology, Netherlands). The obtained data
are calculated and represented as discrimination index (DI) = differ-
ence in time exploring the novel and familiar object/total exploration
time.
2.6.2. Radial arm maze test (RAM)
RAM is a suitable tool for the assessment of both short and long-
term memory. Mice on normal diet were trained for three days (habi-
tuation and learning period) to find food pellets (Dustless Precision
Pellets 45 mg, Sucrose; BioServ, US) in four selected arms of the eight-
arm radial maze (5 × 35 cm for each arm and 5 cm in diameter for the
central platform). The sessions lasted until the animals collected all the
four food pellets or 5 min, whichever came first. The learning ability of
the animals was assessed on the fourth day of the experiment.
Behaviour was video-recorded and analysed with EthoVision XT 11
Software (Noldus Information Technology, Netherlands). The obtained
data are calculated and represented as: reference memory error = en-
tries into unbaited arms (Zhang et al., 2012; Li et al., 2011).
2.6.3. Y-maze test
Spatial working memory was measured after placing the animals in
one of the arms of a Y-shaped maze (arms 5 cm wide x 35 cm long x 10
cm high) for 5-mins (D’Souza et al., 2015). The track of the animals was
obtained with Ethovision XT 11 software (Noldus Information
Technology, Netherlands). The sequence and number of arm entries
were used to determine the percentage of spontaneous alternation by
the following formula: the sequence of visiting the 3 arms (A, B and C)
consecutively in any order was considered as correct alternating be-
haviour (ABC, ACB, BAC, BCA, CAB, CBA) and was divided by the
number of arm entries minus two (representing all possible alternation
sequences). Total number of arm entries was also measured for the
assessment of locomotor activity.
2.6.4. Statistical analysis
Data in all experiments were expressed as mean± SEM. Data were
analysed by factorial ANOVA followed by Bonferroni’s post hoc test
with a value of p<0.05 considered significant. In case of cell/fibre
loss, Mann-Whitney test was used. Learning curve was analysed by
repeated measures two-way ANOVA followed by Bonferroni’s post hoc
test. All statistical analysis was performed using GraphPad Prism
Software 6.0, except for the factorial ANOVA analysis that was per-
formed using STATISTICA Software (TIBCO Software Inc., CA).
3. Results
3.1. Trpa1 mRNA expression in the brain
To elucidate whether Trpa1 is expressed in brain regions relevant to
this work, we performed RT-qPCR in micropunched areas obtained
from TRPA1+/+ or TRPA1−/− animals. Trpa1 expression became sig-
nificant at 35–36 cycles. Trpa1 mRNA was detectable in SI-NBM, hip-
pocampus, somatosensory cortex and trigeminal ganglion isolated from
TRPA1+/+ mice. The Trpa1 expression level of the TRPA1+/+ samples
was compared to their TRPA1-/- counterparts (Fig. 2).
3.2. Aβ1–42-induced cholinergic cell body and fibre loss is significantly
attenuated in TRPA1−/− animals
Cholinergic fibre loss and cholinergic cell loss were detected in the
ipsilateral somatosensory cortex (layer IV-V) and SI-NBM, in WT mice
after Aβ1–42 injection into SI-NBM. The cholinergic fibre loss labelled
with AChE immunohistochemistry was 30.56±1.39 % in TRPA1+/+
Fig. 1. Chronological flowchart for immunohistochemistry (A) and behavioural studies (B).
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mice, while it was only 1.55± 0.91 % in TRPA1−/− animals. The
ChAT-immuno-reactive cell loss in the SI-NBM was 28.68±2.85 % in
WT mice, and it was 2.19±1.70 % in the TRPA1−/− mice (Figs. 3A
and B).
3.3. The effect of Aβ1–42 injection on cognitive functions is attenuated in
TRPA1−/− mice
In the NOR test Aβ1–42 injection had no effect on the locomotion of
mice during habituation (Fig. 4B). There was no side preference during
the exploration phase of the test in all studied groups (Fig. 4C). How-
ever, during the test phase the discrimination ability was significantly
attenuated in Aβ1–42–injected TRPA1+/+ mice (-0.02± 0.11) com-
pared to the naïve controls (0.43±0.08, p = 0.015703). This differ-
ence was not observed between the Aβ1–42-treated and control
TRPA1−/− groups (DI: 0.36± 0.07 and 0.47±0.14; respectively)
showing intact discrimination abilities. This resulted in a significant
difference between Aβ1–42 treated TRPA1+/+ and TRPA1−/− mice (p
= 0.037785). Vehicle injection had no significant effect (TRPA1+/+:
0.20±0.11 and TRPA1−/−: 0.42± 0.09) (Fig. 4D).
In the RAM test animals showed learning ability during the ex-
perimental days except for Aβ1–42 injected TRPA1+/+ mice (Fig. 5A).
There was no change in reference memory error of Aβ1–42 injected
TRPA1+/+ mice over the time (4.0±0.63 on day 2 and 4.0±0.26 on
day 4), while in the vehicle-treated group there was a decrease
(4.33±1.76 on day 2 and 2.50±0.86 on day 4). The same tendency
could be detected in the TRPA1−/− groups (Aβ1–42-injected group:
4.0± 2.0 on day 2 and 2.6±0.49 on day 4; vehicle-treated group:
3.75±0.48 on day 2 and 2.4± 0.51 on day 4). This means, that
Aβ1–42-injected TRPA1−/− animals made significantly less errors (p =
0.019726) on day 4 compared to Aβ1–42-treated TRPA1+/+ mice
(Fig. 5B). There was no significant difference between the two naïve
groups and there was no detectable change in learning ability over time
in these groups (TRPA1+/+: 2.67± 0.33 and TRPA1−/−: 1.4± 0.24
on the day 4).
In the Y-maze test there was no difference in locomotion between
groups reflected by the total number of arm entries. Examining the
spontaneous alterations, each group showed intact working memory
(naïve TRPA1+/+: 15.71±1.91 and 68.42 %±2.32 and TRPA1−/−:
17± 1.19 and 66.31 %±3.61, Aβ1–42-treated TRPA1+/+: 16.4± 1.69
and 67.8 %±2.79; TRPA1−/−: 15.6± 2.4 and 58.92 %±4.73)
(Figs. 5C and D).
4. Discussion
Our study provides the first evidence for the putative role of TRPA1
receptor in neuronal loss and cognitive impairment in Aβ1–42-induced
murine neurotoxicity model. With the help of neuroanatomical eva-
luation and in vivo functional studies we have demonstrated that ge-
netic deletion of TRPA1 receptor attenuates Aβ1–42 toxicity in choli-
nergic neurons in the SI-NBM.
There are several dementia models available: spontaneous, chemi-
cally induced (e.g. Aβ, scopolamine, okadaic acid) and transgenic (e.g.
APP/PS1 knockout mice, tau-related) models (Tayebati, 2006; Neha
Sodhi et al., 2014). None of them is able to show all pathophysiological
features of the human AD. Transgenic models are widely used, because
non-invasive procedures are needed and intracellular Aβ-toxicity can
Fig. 2. Relative quantity of Trpa1 mRNA in the brain and the trigeminal
ganglion. The expression level of Trpa1mRNA was determined in the following
brain regions: SI-NBM, hippocampus, somatosensory cortex of TRPA1+/+ and
TRPA1−/−mice along with trigeminal ganglion by RT qPCR. Samples collected
from the somatosensory cortex of TRPA1−/− animals served as negative tissue
control.
Fig. 3. Morphological changes in the brain
of TRPA1+/+ and TRPA1−/− mice after
Aβ1-42 injection. Representative pictures (A)
and numerical values (B) show the cholinergic
fibre loss in the ipsilateral somatosensory
cortex (layer IV-V) detected with acet-
ylcholinesterase histochemistry. Scale bar: 200
μm, insert scale bar: 20 μm. Representative
pictures (C) and numerical values (D) show the
cholinergic cell body loss in the SI-NBM de-
tected with choline acetyltransferase im-
munohistochemistry. Scale bar: 1000 μm, in-
sert scale bar: 250 μm. Data were presented as
the mean± SEM (n = 6-10) and were ana-
lysed with Mann-Whitney test (*** p<0.001).
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also be triggered (LaFerla and Green, 2012). However, in gene-ma-
nipulated animals, the massive loss of neurons and fibres, as one of the
most typical changes of human disease is not characteristic. In contrast
to the genetic models of AD (e.g. APP/PS1 knockout mice) (Lee et al.,
2016), our experimental approach with intracerebral injection of Aβ
acutely generate AD-like neurotoxicity and cognitive deficits. Early
recognition of the AD is almost impossible because of the atypical
symptoms of the slow progression. The current treatment focuses on the
maintenance of the remaining cholinergic functions applying choli-
nesterase inhibitors and NMDA receptor antagonists (Talesa, 2001;
Eleti, 2016). Despite of some moderately effective drugs, the pharma-
cotherapy of the AD is still an unsolved problem. Therefore, useful
animal models that properly mimic the pathophysiological character-
istics of AD are still essential for the discovery of novel therapeutic
targets. Aβ microinjection elicits significant loss of neuronal elements
with remarkable memory impairment that can be detected with clas-
sical behavioural tests (Morris water maze, Y/T-maze, NOR). This
model represents the later phase of the disease when patients’ relatives
realize the memory problems.
TRPA1 is a widely studied non-selective cation channel, expressed
by the primary afferent neurons regulating pain sensation (Nishida
et al., 2015; Jardín et al., 2017). In addition, increasing evidence has
been published about its function in the CNS: TRPA1 can be found in
neurons of the rodent hippocampus, magnocellular neurosecretory
cells, the visceral afferent pathway and cortex (Nilius et al., 2012;
Kheradpezhouh et al., 2017). Also its expression has been investigated
in glial cells and its putative role in the pathophysiology of AD (Lee
et al., 2016, Shigetomi et al., 2013). Since it is well-known, that TRPA1
is a key regulating receptor of calcium homeostasis, it may influence
cell death or survival (Bosson et al., 2017, Stueber et al., 2017).
Aβ1–42 stereotaxic microinjection caused robust damage of choli-
nergic neurons and fibres in the WT animals, which indicates that this
method is suitable model of the typical pathomorphological changes of
cholinergic neurotoxicity. Interestingly, in TRPA1−/− animals the
Aβ1–42-induced cell and fibre loss of cholinergic neurons were nearly
absent. These results suggest pivotal role of TRPA1 in the neurode-
generative processes of the brain, especially in the basal forebrain
cholinergic neurons. Morphological changes evoked by Aβ injection
Fig. 4. Effects of vehicle or Aβ1-42 injection
on the performance in the novel object re-
cognition (NOR) task in TRPA1+/+ and
TRPA1−/− mice. On day 1 of the 3-day-long
NOR test (A) distance moved (B), on day 2
location preference (C) was measured. On day
3 memory function was determined as dis-
crimination index (D). Data are presented as
the mean± SEM (n = 6-10) and were ana-
lysed by factorial ANOVA followed by
Bonferroni’s post hoc test and location pre-
ference with one sample t-test in comparison to
50.
Fig. 5. Effects of vehicle and Aβ1-42 injec-
tion on the performance in the radial arm
maze (RAM) and Y-maze task in TRPA1+/+
and TRPA1−/− mice. Learning curve on the
basis of reference memory error (A) and the
reference memory error on day 4 (B) was de-
termined in RAM. Spontaneous alternation (C)
and average entries (D) was measured in Y-
maze test. Data are presented as the
mean±SEM (n = 6-10). Learning curve was
analysed by repeated measures two-way
ANOVA followed by Bonferroni’s post hoc test,
and reference memory error and average en-
tries were analysed by factorial ANOVA fol-
lowed by Bonferroni’s post hoc test
(*p<0.05).
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have also been supported by functional investigations. Bilateral ad-
ministration of Aβ1–42 induced significantly impaired memory function
in TRPA1+/+ mice. These changes could be detected in both NOR and
RAM, but Y-maze was not suitable for the demonstration this type of
cognitive impairment. NOR test is one of the most appropriate methods
assessing memory loss in rodents. It has been used in numerous dif-
ferent (transgenic and non-transgenic) AD models. It has several ad-
vantages, such as short testing period, no food restriction is needed, and
it is based on the natural exploratory behaviour of the mice (Zhang
et al., 2012; Grayson et al., 2015). RAM is also frequently used in AD
mouse models (Webster et al., 2014), and it is a suitable for evaluation
of both short- and long-term memory (Puzzo et al., 2014). Despite of
the Aβ treatment, the memory performance of the TRPA1−/− animals
was comparable with the naïve mice in these tests. This means, that the
measured morphological changes are manifested at the behavioural
level. These results verify the observations of the former transgenic
model, that genetic lack of TRPA1 can significantly attenuate the
memory loss (Lee et al., 2016), nevertheless not all of the tests showed
the same results. Our Y-maze methodology was slightly different from
the data of the above mentioned research group. Lee et al. divided Y-
maze into start, familiar and novel arms, and they measured the visiting
activity of mice in the novel arm, which is very similar to the aspect of
NOR. On the contrary, we considered the arms as equal, and the al-
ternation activity was assessed during the experiments. In this case we
gain information about the spatial memory.
Our findings showed that genetic deletion of TRPA1 receptors
substantially inhibited the Aβ1–42-induced cholinergic cell body loss
and fibre loss. We demonstrated that Aβ1–42 injection into the SI-NBM
caused significantly reduced neuronal damage and memory loss in the
TRPA1 KO animals. The exact molecular mechanism, how TRPA1 re-
ceptors contribute to the Aβ1–42-induced cholinergic cell loss is still not
fully elucidated. Previously, Harkany and colleagues published that
Aβ1–42 induces cholinergic cell death via NMDA receptor mediated in-
tracellular Ca2+ increase in SI-NBM (Harkány et al., 2000). We spec-
ulate that TRPA1 receptor-mediated calcium influx may enhance the
neurotoxic effect of the Aβ1–42 due to the cytotoxic Ca2+ overload in
cholinergic neurons in SI-NBM. This theory warrants further in-
vestigation.
5. Conclusion
Our study has presented the first evidence that the genetic lack of
TRPA1 receptor significantly attenuates the Aβ1–42-induced cholinergic
neurotoxicity in the SI-NBM. We also demonstrated that TRPA1 KO
animals show substantially reduced memory loss after Aβ1–42 lesion
compared to the wild-type counterparts. Based on our findings, in-
hibition of the TRPA1 receptors might be a novel promising prospect in
the pharmacotherapy of AD. The limitation of our study is, that its main
conclusions are based exclusively on morphological and functional data
provided by experiments on TRPA1 wildtype and KO mice.
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